AstraZeneca announced that the European Commission (EC) has approved Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere is the first medicine in its class to be approved by the EC in a pMDI. The approval offers patients with COPD an important new choice of inhaler device.
![Maak saaie content interessant: spelen met invalshoeken [3 tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/01/high-angle-shot-of-a-diverse-business-team-hands-p-2023-11-27-05-19-55-utc-1-80x60.jpg)
